Clinical trial Recruiting at 4 sites Observational Ages 18 and up Women only

Molecular analysis of the maternal-fetal interface in preeclampsia

Official title: Molecular Study of the Maternal-fetal Interface Prospectively to the Onset of Preeclampsia Using Single Cell Technology.

Run by Carlos Simon Foundation · NCT06232668 · Data updated 2026-11-12

This study is trying to find specific markers in early pregnancy that could help identify women at risk for preeclampsia, using samples from those undergoing routine testing.

Quick facts

Study typeObservational
Ages18 Years and up
SexWomen only
Enrollment2084 (estimated)
SponsorCarlos Simon Foundation
Academic / other
Locations4 sites (Alicante, Alicante and 3 other locations)
StatusRecruiting
StartedNovember 20, 2023
Main results expectedDecember 2027
Study endsDecember 2027
Registry record updatedNovember 6, 2026
Trial IDNCT06232668 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates for this study are pregnant women over the age of 18 who are between 9 and 14 weeks of gestation and are undergoing chorionic villus biopsy due to a risk of fetal chromosomal abnormalities.

Probably not a fit

Patients with multiple pregnancies or non-evolving pregnancies will not benefit from this study.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to identify molecular markers and aberrant cell types at the maternal-fetal interface during early pregnancy in women at risk for preeclampsia. By collecting chorionic villi samples from pregnant women undergoing aneuploidy testing between 9 and 14 weeks of gestation, the study will utilize single-cell sequencing technology to analyze the molecular profiles associated with preeclampsia. The goal is to characterize the early development of preeclampsia and improve early detection and prevention strategies.

Why it matters

Potential benefit: If successful, this study could lead to early identification and intervention for women at risk of developing preeclampsia, potentially reducing maternal and fetal morbidity and mortality.

How similar studies have gone: While the approach of using single-cell sequencing for early detection of preeclampsia is innovative, similar studies have shown promise in identifying biomarkers for other obstetric complications.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Patients whose written informed consent approved by the Ethics Committee (EC) has been obtained, after having been duly informed of the nature of the study and voluntarily accepted to participate after being fully aware of the potential risks, benefits and any discomfort involved.
* Women over the age of 18 at the time of signing the informed consent form.
* Women who meet at least one of the following criteria at the time of inclusion:

Phase 1 (first trimester): Pregnant women between 9 and 15 weeks of gestation who are scheduled to undergo chorionic villus sampling (CVS) as part of the center's routine clinical practice.

Phase 2 (delivery): Women with an ongoing pregnancy, regardless of gestational age and without the requirement of having participated in Phase 1, who are willing to donate placental and maternal blood samples following delivery.

Exclusion Criteria:

* Women with multiple pregnancy.
* Non-evolving pregnancies (including delayed abortion/foetal orbit).

Where it's running

  • Hospital General Universitario Dr. Balmis
    Alicante, Alicante, Spain
    Recruiting
  • Hospital Clinico Universitario Virgen de la Arrixaca
    Murcia, Murcia, Spain
    Recruiting
  • Hospital Universitario de Canarias
    Santa Cruz de Tenerife, Santa Cruz de Tenerife, Spain
    Recruiting
  • Hospital Universitario y Politécnico La Fe
    Valencia, Valencia, Spain
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Browse more
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.